IRON
Disc Medicine Inc.
NASDAQ: IRON · HEALTHCARE · BIOTECHNOLOGY
$69.23
-5.78% today
Updated 2026-06-05
Market cap
$2.60B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-6.64
Dividend yield
—
52W range
$40 – $100
Volume
0.4M
Disc Medicine Inc. (IRON) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | $322000.00 | $192000.00 | $300000.00 | $100000.00 | $156000.00 | $281000.00 |
| Gross profit | $-322000.00 | $-192000.00 | $-300000.00 | $-100000.00 | $-156000.00 | $-281000.00 |
| Gross margin | — | — | — | — | — | — |
| R&D | $28.17M | $25.17M | $33.44M | $69.26M | $96.67M | $170.64M |
| SG&A | $5.87M | $5.76M | $14.04M | $21.86M | $33.05M | $65.38M |
| Operating income | $-34.04M | $-30.93M | $-47.48M | $-91.13M | $-129.72M | $-236.02M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-33.69M | $-30.90M | $-47.39M | $-76.23M | $-108.27M | $-207.94M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-34.01M | $-30.93M | $-47.48M | $-76.33M | $-108.43M | $-208.22M |
| Interest expense | $6.83M | $2.16M | $737000.00 | $0.00 | $572000.00 | $3.61M |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-40.84M | $-35.97M | $-46.09M | $-76.43M | $-109.36M | $-212.18M |
| Net income growth (YoY) | — | +11.9% | -28.1% | -65.8% | -43.1% | -94.0% |
| Profit margin | — | — | — | — | — | — |
Frequently asked questions
How much free cash flow does IRON generate?
IRON produced $-181.33M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is IRON's balance sheet healthy?
IRON holds $91.14M in cash and equivalents against $29.16M in long-term debt, on $739.83M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.